<p>The first randomised trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular arrhythmias (VAs) reduces the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy and unplanned hospitalisation in patients with no previously recorded VAs. The late-breaking science is presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).</p>
<p>Principal investigator Dr. David Zizek of the University Medical Centre Ljubljana, Slovenia said: “In everyday clinical practice, ventricular tachycardia (VT) ablation is still often regarded as a last resort in the management of patients with ischaemic cardiomyopathy. We hypothesised that ablation early in the course of the disease, when patients have a lower burden of comorbidities, might be associated with fewer periprocedural complications and impr
Johnson & Johnson acquires Shockwave Medical, bolstering its presence in cardiovascular intervention. The move marks a strategic shift, with around $30 billion invested in MedTech over 18 months.
Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes
Extends Johnson & Johnson MedTech’s Position in.
J&J adds Shockwave Medical to its cardiovascular collection with $13.1B deal fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.